Dermatology- January 2014

Dermatitis Atopic/Contact & Eczema

 

Prevalence, Incidence and Predicttive Factors for Hand Eczema in Young Adults (full text link)

BMC Dermatology 2013, 13:14 

Arne Johannisson1*, Ann Pontén23 and Åke Svensson45

This research was to investigate the prevalence and incidence of hand eczema and to evaluate risk factors for development of hand eczema in young adults. Subjects and methods; This is a prospective follow-up study of 2,403 young adults, 16 – 19 years old in 1995 and aged 29 – 32 years, 13 years later, in 2008. They completed a postal questionnaire that included questions regarding one-year prevalence of hand eczema, childhood eczema, asthma, rhino-conjunctivitis and factors considered to affect hand eczema such as hand-washing, washing and cleaning, cooking, taking care of small children and usage of moisturisers. These factors were evaluated with the multinominal logistic regression analysis.

It was found that after 13 years an increased 1-year prevalence of hand eczema was found. The significant risk factors for hand eczema changed over time from endogenous to exogenous factors.

Protocol for a randomised trial on the effect of group education on skin-protective behaviour versus treatment as usual among individuals with newly notified occupational hand eczema – the prevention of Hand Eczema (PREVEX) Trial (full text link)

BMC Dermatology 2013, 13:16 

Maja Hvid Fisker1, Tove Agner2*, Jane Lindschou3, Jens Peter Bonde1, Kristina Sophie Ibler4, Christian Gluud3, Per Winkel3 and Niels E Ebbehøj1

Background:The incidence of occupational hand eczema is approximately 0.32 per 1,000 person years. The burden of the disease is high, as almost 60% has eczema related sick leave during the first year after notification, and 15% are excluded from the workforce 12 years after disease onset. New treatments and prevention strategies are needed.

Atopic dermatitis and skin allergies – update and outlook (full text link)

Allergy Vol.68, iss.12 pgs 1509-1519, Dec.2013

A. Wollenberg & K. Feichtner

Abstract:

During the last few years, an impressive amount of experimental studies and clinical trials have dealt with a variety of distinct topics in allergic skin diseases –especially atopic dermatitis. In this update, we discuss selected recent data that provide relevant insights into clinical and pathophysiological aspects of allergic skin diseases or discuss promising targets and strategies for the future treatment of skin allergy. This includes aspects of barrier malfunction and inflammation as well as the interaction of the cutaneous immune system with the skin microbiome

and diagnostic procedures for working up atopic dermatitis patients. Additionally, contact dermatitis, urticaria, and drug reactions are addressed in this review.

This update summarizes novel evidence, highlighting current areas of uncertainties and debates that will stimulate scientific discussions and research activities in the field of atopic dermatitis and skin allergies in the future.

 

Efficacy and safety of systematic treatments for moderate-to-severe atopic dermatitis: A systematic review (link to abstract only)

 

 

Evelien Roekevisch, MDa, Phyllis Ira Spuls, MD, PhDa, Denise Kuester, BAb, c, Jacqueline Limpens, PhDa, Jochen Schmitt, MD, MPHb, c,

Background:

Many patients with moderate-to-severe atopic dermatitis (AD) require systemic immunomodulating treatment to achieve adequate disease control.

Objective:

We sought to systematically evaluate the efficacy and safety of systemic treatments for moderate-to-severe AD.

 

Conclusion:

Although 12 different interventions for moderate-to-severe AD have been studied in 34 RCTs, strong recommendations are only possible for the short-term use of cyclosporin A. Methodological limitations in the majority of trials prevent evidence-based conclusions. Large head-to-head trials evaluating long-term treatments are required

 

Journal of Allergy and Clinical Immunology          (available on-line 24th Oct, 2013)

Contact Allergy from disperse dyes in textiles-a review (full text link)

Contact Dermatitis

(Article first published online: 10 OCT 2012)

Laura Malinauskiene1,2,*, Magnus Bruze2, Kristina Ryberg2,3, Erik Zimerson2, Marléne Isaksson

Summary:

Several disperse dyes (DDs) are still considered to be themost important allergens in textile dermatitis, but there are sparse data about their current use in textiles. The aim of this review was to evaluate published studies and reports on contact allergy to DDs published in PubMed during the last 22 years (1990–2012). Prevalence data are provided by studyand by dye, aswell as by the described clinical peculiarities of DD dermatitis.We reviewed 54 studies. In total, 26 DDs were tested. The average prevalence in screening studies was >1% for Disperse Blue 106, Disperse Blue 124, and Disperse Orange 3. There is a lack of data on patch testing with Disperse Blue 26, Disperse Blue 102, Disperse Orange 37, Disperse Orange 149, Disperse Yellow 23 and Disperse Yellow 49, which are listed as allergens by the EU commission. It is necessary to check the purity and identity of dyes used for patch testing, confirm the clinical relevance of positive reactions by patch testing with suspected textiles, and, if the results are positive, determine the culprit dye.

Acne and Rosacea

 

Women’s experiences with isotretonoin risk reduction counselling (link to abstract and full text)

JAMA Dermatol. Published online November 20, 2013

Carly A. Werner, BA1; Melissa J. Papic, BS2; Laura K. Ferris, MD, PhD3; Jessica K. Lee, MD4; Sonya Borrero, MD2,5; Noel Prevost, PA3; Eleanor Bimla Schwarz, MD, MS2,4,5

Objective:To explore women’s experiences with counseling about isotretinoin risk

Conclusions and Relevance: Since few clinicians provide women information on highly

effective (ie, intrauterine or subdermal) contraceptives, the iPLEDGE program increases

anxiety about isotretinoin more than it helps women feel protected from the teratogenic risks

of isotretinoin.

 

Analysis of Facial Skin-Resident Microbiota in Japanese Acne Patients (link to abstract only)

Dermatology(DOI:10.1159/000356777)

Numata S.a· Akamatsu H.b· Akaza N.a, c· Yagami A.a· Nakata S.c· Matsunaga K.a

Mirvaso Gains CHMP Support for Rosacea Erythema Treatment (Medscape article..may require registration; it is free)

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing of brimonidine tartrate 3 mg/g topical gel (Mirvaso, Galderma) for the symptomatic treatment of facial erythema of rosacea in adult patients

Melanoma

 

British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014 (link to abstract only)

On-line Dec 7th BJD

Precursor B-or T-lymphoma presenting with cutaneous involvement: A series of 13 cases including 7 cases of cutaneous T-1… (link to abstract only)

JAMA Dermatol. Published online December 4th,2013 (in press, corrected proof)

Woo Jin Lee, Hye Rim Moon, Chong Hyun Won, Sung Eun Chang, Jee Ho Choi, Kee Chan Moon, Mi Woo Lee,

Background:Lymphoblastic lymphoma (LBL) is a rare neoplasm of precursor lymphocytes, and cutaneous involvement is present in less than 20% of cases.

Objective:We sought to describe the clinical and histopathological features of cutaneous LBL.

Conclusion:This study compared the clinical features of T-LBL and B-LBL, in particular the affected sites and number of skin lesions. Cutaneous T-LBL is likely to be accompanied by disseminated disease and has a relatively poor prognosis compared with B-LBL.

Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial

(Lancet oncology on-line Dec.2013)

    Fiona Bath-Hextall, Mara Ozolins, Sarah J Armstrong,

Graham B Colver, William Perkins, Paul S J Miller,

Prof Hywel C Williams,

Tumor Volume as a Prognostic Factor in Resectable Malignant Melanoma (link to full text)

Dermatology (published on-line 06.12.2013)

Voss B. · Wilop S. · Jonas S. · El-Komy M.H.M. · Schaller J. · von Felbert V. · Megahed M.

Abstract

Background: Vertical tumor thickness according to Breslow and histological ulceration are still the most powerful predictors for the clinical outcome of resectable cutaneous malignant melanoma (MM) without lymph node infiltration. It has been proposed that tumor volume in MM may also be of prognostic relevance.

Methods: We retrospectively analyzed the prognostic impact of tumor volume and other established risk factors in 122 MM patients with a median follow-up period of 39.7 months.

Results: We found the logarithmic tumor volume to be a better prognostic factor compared to Breslow tumor thickness in multivariate analysis. MM with a tumor volume below a threshold of 140 mm3 had a significantly higher relapse-free survival after 5 years of 98% compared to 47% in larger MMs (p < 0.0001).

Conclusion: In some melanomas with a low tumor thickness, a higher tumor volume appeared to be linked to a higher risk of disease recurrence. Inclusion of tumor volume into the risk assessment of resectable MM may be of benefit in the future.

Melanoma Associated with the use of Melanotan-11

(link to full text)

Kasper Fjellhaugen Hjuler a, b Henrik Frank Lorentzen a

       Dermatology(published on-line18.12.2013)

Abstract

Background:Unlicensed use of melanotan-II

(MT-II) to promote skin pigmentation has become

prevalent amongst young people attending

fitness centres. We present a case where the melanocyte stimulation of MT-II in combination with the use of sun tanning beds coincided with cutaneous melanoma.

Observation: A 20-year-old woman with

Fitzpatrick skin type II was referred to a dermatology

clinic. Clinical examination revealed a suspicious black melanocytic lesion in her left gluteal region. Furthermore, her skin was universally intensely pigmented. The melanocytic lesion was excised, and histology confirmed the diagnosis of melanoma.

Three months prior to the excision the patient had conducted a 3- to 4-week courseof self-injections with MT-II, intending an augmentation of sunbed tanning.

Conclusionsand Relevance:This observation

brings attention to the potential risks related to the use of the cyclic α-melanocytestimulating hormone analogue MT-II. There are several hazardous aspects of the possible widespread use of MT-II. As the drug is unlicensed and incompletely tested, the extent and types of adverse effects are unknown.

 

A Case of Malignant Peripheral Nerve Sheath Tumor with Rhabdomyoblastic Differentiation: Malignant Triton Tumor (full text link)

Case Reports in Dermatology( published on-line 24.12.2013)

Kenichiro Mae Yukihiko Kato Kae Usui Namiko Abe Ryoji Tsuboi

Abstract

Malignant peripheral nerve sheath tumors (MPNST) constitute a rare variety of soft tissue sarcomas thought to originate from Schwann cells or pluripotent cells of the neural crest. Malignant triton tumor (MTT), a very rare, highly aggressive soft tissue tumor, is a subgroup of MPNST and is comprised of malignant Schwann cells coexisting with malignant rhabdo-myoblasts. We herein report the case of a 24-year-old man who presented a subcutaneous mass in his right thigh. The mass was removed surgically in its entirety and radiation therapy was applied locally to prevent tumor regrowth. Nonetheless, the patient died 10 months after surgery from metastases to the lung and brain. He presented neither cafe-au-lait spots nor cutaneous neurofibromas. The histopathology showed a transition from a neurofibroma to an MTT, making this the second report of an MTT arising from a neurofibroma without neurofibromatosis type 1, an autosomal dominant disorder with which 50–70% of tumors reported in previous studies were associated. A histopathological examination using immunostaining with desmin confirmed this diagnosis. MTT has a poorer prognosis than MPNST and should therefore be regarded as a distinct clinical entity.

Statin use is not associated with reduced risk of skin cancer: A meta-analysis (link to abstract only)

British Journal of Cancer, 12/26/2013 Clinical Article

Li X, et al. –

There is contradictory evidence about the association between statin and skin cancer. The meta–analysis does not support a potential role of statin use in the prevention of skin cancer

Methods

·         Literature search in PubMed and Web of Science was undertaken up to June 2013.

·         Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated.

Results

·         A total of 21 articles with 29 studies were identified.

·         No association was found between statin and skin cancer among neither melanoma (RR, 0.94; 95% CI, 0.85–1.04) nor non–melanoma skin cancer (RR, 1.03; 95% CI, 0.90–1.19).skin cancer.

Paediatric Dermatology

 

An Infant With Atrophic and Wrinkled Abdominal Skin (link to first page preview only)

Mahwish Irfan, MD1; Kate Lowenthal, MD2; Thomas Helm, MD2; Zdenka Safar, MD3; Ilene Rothman, MD2

JAMA Dermatology 04.12.2013

Congenital erosive and vesicular dermatosis with reticulated supple scarring: Unifying clinical features (link to abstract only, full text available to read in Bell Library)

JAAD, vol.69,iss.6, pgs.909-15

Brook E. Tlougan, MDa, Amy S. Paller, MDb, Julie V. Schaffer, MDc, Joshua O. Podjasek, MDd, Jenny A. Mandell, MDe, Xuan H. Nguyen, MDf, Mary K. Spraker, MDg, h, Ronald C. Hansen, MDi, j, k

New approaches to the prevention of childhood atopic dermatitis (full text link)

Allergy, 26.12.2013

C. Flohr, J. Mann

Abstract

There has been a steep rise in the burden of atopic dermatitis (AD), and up to20% of children in developed countries now suffer of the disease. At present,treatment at best achieves symptom control rather than cure, and there is astrong need to identify new methods of disease prevention. While earlierapproaches focused on allergen avoidance strategies, there has been a clear shifttowards attempts to induce tolerance and enhancement of skin barrier function,as skin barrier breakdown plays an important role in AD development. This articlereviews the latest developments in the prevention of AD

Severe Demodexfolliculorum-Associated Oculocutaneous Rosacea in a Girl successfully treated with Ivermectin (link to abstract only)

JAMA DermatologyPublished online November 27, 2013.

Megan Brown, MD1; Angela Hernández-Martín, MD2; Ana Clement, MD3; Isabel Colmenero, MD4; Antonio Torrelo, MD2

Psoriasis

 

Psoriasis is independently associated with non-alcoholic fatty liver disease in patients 55 years old or older: Results from a population based study (link to abstract only)

JAAD on-line 24.12.2013

Ella A.M. van der Voort, MDa, Edith M. Koehler, MDEmmilia A. Dowlatshahi, MDa, Albert Hofman, MD,PhDc, Bruno H. Stricker, MB, PhDc, d, Harry L.A. Janssen,PhDb, Jeoffrey N.L. Schouten, MD, PhDb,Tamar Nijsten, MD, PhDa, ,

Objective:We sought to compare the prevalence of NAFLD in people with psoriasis and those without psoriasis.

Conclusion:Elderly participants with psoriasis are 70% more likely to have NAFLD than those without psoriasis independent of common NAFLD risk factors.

Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. (link to full text)

Ann Rheum Dis 2014; 73; 149-153

Alexis Ogdie1, Kevin Haynes2, Andrea B Troxel2, Thorvardur Jon Love3, Sean Hennessy2, Hyon Choi4, Joel M Gelfand5

The objective of this study was

to examine the risk of mortality in patients with PsA

compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA).

 

Conclusions Patients with RA and psoriasis have

increased mortality compared with the general

population but patients with PsA do not have a significantly increased risk of mortality.

 

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry(link to abstract only)

JAMA Derm Published on-line 18.12.2013

Stefano Piaserico, MD, PhD Simone Cazzaniga, PhD Math Sergio Chimenti, MD, PhD Alberto Giannetti, MD, PhD Mara Maccarone, BA Mauro Picardo, MD Andrea Peserico, MD Luigi Naldi,

This study reported that in patients who switched TNF-alfa therapy (n=105) 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks.

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis(link to abstract only)

JAMA Derm On-line first 18.12.2013

Stef P. Menting, MD1; Paula P. M. van Lümig, MD2; Anna-Christa Q. de Vries, MD1; Juul M. P. A. van den Reek, MD2; Desiree van der Kleij, PhD3; Elke M. G. J. de Jong, MD, PhD2; Phyllis I. Spuls, MD, PhD1; Lidian L. A. Lecluse, MD, PhD1

In this multicentre cohort study of patients receiving adalimumab therapy for plaque-type psoriasis (n=80), antidrug antibody formation was seen in 49% (by 24 weeks in most cases). It was strongly correlated with adalimumab concentration, and influenced clinical responseAffiliationsDermatology Unit, Department of Medicine, University of Padua, Padua, Italy

Venous

 

Endovenous laser ablation of the great and short saphenous veins with a 1320-nm neodymium:yttrium-aluminum-garnet laser: Retrospective case series of 1171 procedures (link to abstract only)

JAMA Derm On-line first 04.12.2013

Danielle K. Moul, MD, FAADa, Leland Housman, MD, FACSb, Sara Rominec, Hubert Greenway, MD, FAADc

Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial (link to abstract)       ( pdf link via Science Direct)

Lancet On-line first 06.12.2013

Dr Susan R Kahn, MDa, Stan Shapiro, PhDa, b, Philip S Wells, MDc, d, Marc A Rodger, MDd, e, Michael J Kovacs, MDf, David R Anderson, MDg, h, Vicky Tagalakis, MDa, Adrielle H Houweling, MSca, Thierry Ducruet, MSca, Christina Holcroft, ScDi, j, Mira Johri, PhDk, l, Susan Solymoss, MDn, o, Marie-José Miron, MDq, Erik Yeo, MDr, Reginald Smith, PharmDs, Sam Schulman, MDt, u, v, Jeannine Kassis, MDw, Clive Kearon, MBt, Isabelle Chagnon, MDm, Turnly Wong, MDx, Christine Demers, MDy, Rajendar Hanmiah, MDz, Scott Kaatz, DOaa,Rita Selby, MBBSab, Suman Rathbun, MDac, Sylvie Desmarais, MDad, Lucie Opatrny, MDp, Thomas L Ortel, MDae, Jeffrey S Ginsberg, MDt,

Recurrent cutaneous necrotizing eosinophilic vasculitis: a case report and review of the literature (full text link)

Diagnostic Pathology2013, 8:185 

Wenfei Li13, Wang Cao3, Haiyan Song1, Yanxia Ciu1, Xianmei Lu12* and Furen Zhang12

Abstract:We report a case of recurrent cutaneous necrotizing eosinophilic vasculitis (RCNEV) in a 57-year-old male. The patient presented with papules and pruritus of the lower limbs of more than 1 month duration, and with angioedema and intensively pruritic, necrotizing lesions of the bilateral anterior tibias and feet for 2 weeks. Treatment with systemic corticosteroids was administered for 1 month, and resulted in a significant improvement. We also present a review of the pertinent literature and discuss the clinical features, histopathological features, and differentiation of RCNEV.

New and Updated Cochrane Reviews

 

Endovenous ablation therapy (LASER or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veinsProtocolNew

(new published on-line 20.12.2013)

Genetic testing for prevention of severe drug-induced skin rash

(new published on-line 19.12.2013)

Hydrocolloid dressings for healing venous leg ulcers

(new published on-line 10.01.2014)

Interventions for the symptoms and signs resulting from jellyfish stings

(new published on-line 09.12.2013)

Radiotherapy and corticosteroids for preventing and treating keloid scars

(new published on-line 19.12.2013)

Interventions for cutaneous sarcoidosis

(new published on-line 19.11.2013)

Antibiotics and antiseptics for venous leg ulcers

(updated published on-line 10.01.2014)

Compression stockings for the initial treatment of varicose veins in patients without venous ulceration

(updated published on-line 09.12.2013)

Hyperbaric oxygen therapy for treating acute surgical and traumatic wounds

(updated published on-line 16.12.2013)

Psychological and educational interventions for atopic eczema in children

(updated published on-line 07.01.2014)

New England Journal of Medicine

 

Images in Clinical Medicine

Evolution of a diabetic foot infection (Dec.5th)

Cutaneous and Gastrointestinal purpura (Nov.7th)

Aquagenic Wrinkling of the Palms in a Patient with Cystic Fibrosis

N Engl J Med 2013; 369:2362-2363

In this case report, ivacaftor was used as therapy and as an indicator to show that aquagenic wrinkling of the palms in a patient with the G551D cystic fibrosis mutation is related to the presence of this cysticfibrosis transmembrane conductance regulator variant.

To the Editor: Cystic fibrosis is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes for a protein involved in transepithelial ion transport. Aquagenic wrinkling of the palms, a transient phenomenon of the skin…

Link to pdf

Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis(link to pdf)

December 18, 2013

van Bon L., Affandi A.J., Broen J., et al.

Systemic sclerosis (also called scleroderma) is a complex heterogeneous fibrosing autoimmune disorder with an unknown pathogenesis. The way in which its three major pathologic hallmarks — extensive fibrosis, vasculopathy, and immune dysfunction — are interconnected is unknown. Mechanistic…

Case 39-2013- A 57-Year –Old Woman with Painful Bullous Skin Lesions

(full text available to read in Bell Library)

December 19th, 2013. 369: 2438-2449

Roh E.K.Vleugels R.A.Hoang M.P.

Presentation of Case. Dr. Amir Aboutalebi (Dermatology): A 57-year-old woman was admitted to this hospital because of recurrent painful bullous and erosive skin lesions. Approximately 19 months before admission, 1 week after the patient had begun taking citalopram, the development of oral erosions,…

JAMA/JAMA Derm

 

Prosthetic Reconstruction of Complicated Auricular Defects : Use of a Hybrid Prosthetic Fabrication Technique (link to first page preview)

JAMA Facial Plast Surg. Published online December 05, 2013

Levi G. Ledgerwood, MD1; Janet Chao, MS2; Travis T. Tollefson, MD, MPH1

A multidisciplinary rehabilitative approach to patients treated for head and neck malignant neoplasms aims to address both the surgical defects and functional deficits. Free tissue transfer for reconstruction of large facial defects is considered the gold standard for many defects.1 Prosthetic facial restoration can be useful when surgical reconstruction is precluded by medical comorbidities, defect size or location, or patient preference.2

Pruritus in the Older Patient (link to abstract only, full text available to read in Bell Library)

JAMA. 2013;310(22):2443-2450.

Timothy G. Berger, MD1; Melissa Shive, MD, MPH2; G. Michael Harper, MD3

Using a patient case as an example, this clinical review discusses the aetiology, diagnosis, and treatment of pruritus in the elderly. It is intended to provide generalist physicians with an evidence-based treatment approach for this patient group.

BMJ

 

Breast Infection (full text link)

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f3291 (Published 16 December 2013)

J Michael Dixon

Overview:

·         Breast infection during breastfeeding is less common than it used to be

·         Early prescription of appropriate antibiotics in infection limits abscess formation

·         Delay in referral to breast clinics of patients with lactating infection that does not settle rapidly with antibiotics continues to be a problem

·         Breast abscesses can be aspirated or drained through a very small skin incision

·         Breast cancer should be excluded in patients with inflammatory changes that do not settle rapidly on appropriate therapy

 

Diagnosis and management of hyperhidrosis (full text link)

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f6800 (Published 25 November 2013)

Summary points

·         The prevalence of hyperhidrosis is estimated at 1%, but it is probably much higher owing to low levels of reporting to primary care

·         Onset tends to be at puberty, when axillary apocrine glands start to function, making axillary hyperhidrosis the most common type

·         Although prevalence is equal among the sexes, women are more likely to present to primary practice

·         Initial treatment in primary care should include lifestyle and behavioural advice and topical agents

·         If this approach does not work, refer to a dermatologist

·         Sympathectomy is reserved for people in whom conservative measures are ineffective or poorly tolerated, and who accept the risk of compensatory hyperhidrosis

Pruritus in the Older Patient (link to abstract only, full text available to read in Bell Library)

A Clinical Review

JAMA.2013;310(22):2443-2450

Timothy G. Berger, MD1; Melissa Shive, MD, MPH2; G. Michael Harper, MD3

Miscellaneous

 

Behind the Headlines…Fatty acids in marine algae could treat skin problems

The study was carried out by two researchers from the School of Natural Sciences at the University of Stirling in Scotland and was published in the peer-reviewed open access scientific journal Marine Drugs. The study can be read free on-line or downloaded as a PDF (link)

Mobile Applications in Dermatology (link to abstract only)

JAMA Dermatol.2013;149(11):1300-1304.

Ann Chang Brewer, MD1; Dawnielle C. Endly, DO2; Jill Henley, DO2; Mahsa Amir, MD3; Blake P. Sampson, MD4; Jacqueline F. Moreau, MS5; Robert P. Dellavalle, MD, PhD, MSPH3,6,7

It’s right there in your hand-underuse of mobile applications in dermatology (link to abstract and first page preview)

JAMA Dermatol.2013;149(11):1305

Ashish C. Bhatia, MD1

Protection of Patients’ Right to Privacy in Clinical Photographs, Video, and Detailed Case Descriptions(free on-line access)

JAMA Dermatol.2014;150(1):14-16

June K. Robinson, MD1; Ashish C. Bhatia, MD1; Jeffrey P. Callen, MD2

A Case of Autosomal Recessive Woolly Hair/Hypotrichosis with Alternation in Severity: Deterioration and Improvement with Age (open access)

Case Rep Dermatol 2013;5:363–367

 

Naoko Matsunoa Makoto Kunisadaa Haruhisa Kankia Yutaka Simomurab Chikako Nishigoria

 

An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa

JAAD Volume 70, Issue 2, February 2014, Pages 243–251

Kieron S. Leslie, DTM&H, FRCP, Shivani V. Tripathi, MD, Tien V. Nguyen, MD, Mariela Pauli, MS, Michael D. Rosenblum, MD, PhD

Spontaneous Cutaneous Endometriosis of the Umbilicus (link to full text)

Case Rep Dermatol 2013;5:368-372Gin T.J.a· Gin A.D.a· Gin D.b· Pham A.c· Cahill J.b

 

Long-Term Stability and Safety of Transgenic Cultured Epidermal Stem Cells in Gene Therapy of Junctional Epidermolysis Bullosa (link to pdf)

Stem Cell Reports j Vol. 2 j 1–8 j January 14, 2014

Laura De Rosa,1,5 Sonia Carulli,1,5 Fabienne Cocchiarella,1 Daniela Quaglino,2 Elena Enzo,1

Eleonora Franchini,1 Alberto Giannetti,3 Giorgio De Santis,4 Alessandra Recchia,1 Graziella Pellegrini,1

and Michele De Luca1,*

 

The Effect of Q-Switched Nd:YAG 1064 nm/532 nm Laser in the Treatment of Onychomycosis In Vivo

Dermatology Research and Practice
Volume 2013 (2013), Article ID 379725, 10 pages
http://dx.doi.org/10.1155/2013/379725

Kostas Kalokasidis,1 Meltem Onder,2,3 Myrto-Georgia Trakatelli,4  Bertrand Richert,5 and Klaus Fritz2,6,7,8

 

This work is licensed under the Creative CommonsAttribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

The following sources have been searched for evidence

  •          Allergy
  •          Annals of the Rheumatic Diseases
  •          BMC Dermatology
  •          British Journal of Cancer
  •          British Medical Journal
  •          Case Reports in Dermatology
  •          Cochrane
  •          Contact Dermatitis
  •          Dermatology
  •          Dermatology Research and Practice
  •          Diagnostic Pathology
  •          Histopathology
  •          Journal of Allergy and Clinical Immunology
  •          Journal of the American Academy of Dermatology
  •          Lancet + Lancet Oncology
  •          JAMA
  •          JAMA Dermatology
  •          Medscape
  •          NEJM
  •          NHS Headlines